Protalix BioTherapeutics Inc (PLX)

0.64
AMEX : Health Care
Prev Close 0.65
Day Low/High 0.63 / 0.67
52 Wk Low/High 0.61 / 1.78
Avg Volume 74.00K
Exchange AMEX
Shares Outstanding 99.81M
Market Cap 64.88M
EPS 0.60
P/E Ratio 2.41
Div & Yield N.A. (N.A)

Latest News

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Protalix BioTherapeutics To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF

Protalix BioTherapeutics To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF

Positive Pre-Clinical Data for PRX-106 Oral Anti-TNF in NASH

Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results

Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results

Net Losses Narrowed With Clinical Progress in All Three Product Candidates

Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF

Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF

Favorable Safety and Tolerability Data Demonstrates Biological Activity in the Gut and Activation of Regulatory T Cells

Protalix BioTherapeutics Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease

Protalix BioTherapeutics Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease

Interim Efficacy and Safety Results to be Presented at WORLD Symposium

Protalix BioTherapeutics Announces New Strategy For Accelerated Growth

Protalix BioTherapeutics Announces New Strategy For Accelerated Growth

Prioritizing Pipeline Candidates to Focus on Bio-Better Products With a Clear Competitive Advantage

5 Stocks Ready to Break Out and Soar Higher

5 Stocks Ready to Break Out and Soar Higher

These stocks look ready to break out and trade higher from current levels.

Interesting PLX Put And Call Options For May 2015

Interesting PLX Put And Call Options For May 2015

Investors in Protalix BioTherapeutics Inc saw new options become available this week, for the May 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 213 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.